Fixed-dose combinations of antiretrovirals are multiple antiretroviral drugs combined into a single pill, which helps reduce pill burden. They may combine different classes of antiretrovirals or contain only a single class. Licensed fixed-dose combinations are shown in the table below.
| Brand Name | Drug Names (INN) | Date of FDA Approval | Company |
|---|---|---|---|
| Combivir | zidovudine + lamivudine | September 26, 1997 | GlaxoSmithKline |
| Trizivir | abacavir + zidovudine + lamivudine | November 15, 2000 | GlaxoSmithKline |
| Kaletra | lopinavir + ritonavir | September 15, 2000 | Abbott Laboratories |
| Epzicom (in USA) Kivexa (in Europe) |
abacavir + lamivudine | August 2, 2004 | GlaxoSmithKline |
| Truvada | emtricitabine + tenofovir | August 8, 2006 | Gilead Sciences |
| Atripla | efavirenz + emtricitabine + tenofovir | July 12, 2006 | Gilead Sciences Bristol-Myers Squibb |
| Complera | rilpivirine + emtricitabine + tenofovir | August 10, 2011 | Gilead Sciences Johnson & Johnson |
| Stribild | elvitegravir + cobicistat + emtricitabine + tenofovir | August 27, 2012 | Gilead Sciences |
Famous quotes containing the word combination:
“By the “mud-sill” theory it is assumed that labor and education are incompatible; and any practical combination of them impossible. According to that theory, a blind horse upon a tread-mill, is a perfect illustration of what a laborer should be—all the better for being blind, that he could not tread out of place, or kick understandingly.... Free labor insists on universal education.”
—Abraham Lincoln (1809–1865)